5-Brom-2-thiophenaldehyd-diethylacetal | 5370-20-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-Brom-2-thiophenaldehyd-diethylacetal
• 英文别名: 2-Bromo-5-(diethoxymethyl)thiophene
• CAS: 5370-20-7
• 化学式: C₉H₁₃BrO₂S
• 分子量: 265.171
• InChiKey: HEKKQBZTQMVFOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  46.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Brom-2-thiophenaldehyd-diethylacetal 在 吡啶 、 锌 作用下， 以 氯仿 、 溶剂黄146 为溶剂， 反应 35.17h， 生成 (E)-5-(pyridin-3-ylmethyl)-2-(2-ethoxycarbonylvinyl)thiophene
  参考文献：
  名称：

  Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives

  摘要：

  The enzyme thromboxane (TX) synthetase is inhibited by pyridine. The beta-substituted pyridine derivatives showed higher inhibitory potency than the gamma-substituted ones having the same side chain. Among the beta-substituted derivatives containing the omega-carboxyalkyl group, the compounds with 6-8 carbon atoms in the side chain were especially effective. The derivatives holding the phenylene group in the side chain exhibited much higher inhibitory activity than those of the alkylene type. Among them, (E)-3-[4-(3-pyridylmethyl)phenyl]-2-methylacrylic acid hydrochloride (5a) had the highest potency (IC50 = 3 x 10(-9) M). The beta-substituted pyridine derivatives and 1-substituted imidazole derivatives which had the same side chain showed almost the same potency. The beta-substituted pyridine derivatives do not inhibit arachidonic acid cyclooxygenase or prostaglandin I2 synthetase, two other enzymes of the arachidonic cascade.

  DOI：

  10.1021/jm00142a006
• 作为产物：
  描述：

  5-溴噻吩-2-甲醛 、 原甲酸三乙酯 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 6.0h， 以93.86%的产率得到5-Brom-2-thiophenaldehyd-diethylacetal
  参考文献：
  名称：

  三芳基硼烷-低聚噻吩-双氰基乙烯基三重态的聚集诱导发射和传感特性

  摘要：

  （DCV）偶联物的设计，合成和一个新的三芳基硼系列，低聚噻吩-二氰基乙烯基的聚集诱导的发射性质4 - 6（A-d-A”型分子构型）的报告。的光学性质4 - 6可以通过审慎地改变缺电子硼和二氰基乙烯基单元之间的噻吩单元的数目来调节。与具有噻吩间隔基的化合物5和4相比，具有噻吩间隔基的化合物6分别显示出高度红移的吸收和发射。化合物5和6在水/ THF混合物中显示出聚集诱导的排放增强。化合物5和6还显示出取决于溶剂粘度的发射特性。对于小阴离子（例如氟和氰化物），所有这三种化合物均显示出不同的光学响应。涂有化合物的滤纸条5和6可以检测˚F -和CN -在具有不同的比色反应的水性介质。

  DOI：

  10.1002/chem.201603349

文献信息

• Synthesis and properties of tetrathiafulvalenes bearing 6-aryl-1,4-dithiafulvenes
  作者：Aya Yoshimura、Hitoshi Kimura、Kohei Kagawa、Mayuka Yoshioka、Toshiki Itou、Dhananjayan Vasu、Takashi Shirahata、Hideki Yorimitsu、Yohji Misaki

  DOI：10.3762/bjoc.16.86

  日期：——

  Novel multistage redox tetrathiafulvalenes (TTFs) bearing 6-aryl-1,4-dithiafulvene moieties were synthesized by palladium-catalyzed direct C–H arylation. In the presence of a catalytic amount of Pd(OAc)2, P(t-Bu3)·HBF4, and an excess of Cs2CO3, the C–H arylation of TTF with several aryl bromides bearing 1,3-dithiol-2-ylidenes took place efficiently to produce the corresponding π-conjugated molecules

  通过钯催化的直接C–H芳基化反应合成了带有6-芳基-1,4-二硫富烯基的新型多级氧化还原四硫富瓦烯（TTF）。在催化量的Pd（OAc）2，P（t- Bu 3）·HBF 4和过量的Cs 2 CO 3存在下，TTF的C–H芳基化与数个带有1,3-芳基溴的芳基化二硫醇-2-亚烷基有效地发生以产生相应的π-共轭分子。我们还通过数字仿真成功地估算了所获得化合物的每个氧化步骤中的氧化电位和电子数量。
• Aggregation-Induced Emission and Sensing Characteristics of Triarylborane-Oligothiophene-Dicyanovinyl Triads
  作者：George Rajendra Kumar、Samir Kumar Sarkar、Pakkirisamy Thilagar

  DOI：10.1002/chem.201603349

  日期：2016.11.21

  highly red‐shifted absorption and emission compared to 5 and 4 with bithiophene and monothiophene spacers, respectively. Compounds 5 and 6 show aggregation‐induced emission enhancement in water/THF mixtures. Compounds 5 and 6 also showed solvent viscosity dependent emission characteristics. All the three compounds show distinct optical responses for small anions such as fluoride and cyanide. Filter

  （DCV）偶联物的设计，合成和一个新的三芳基硼系列，低聚噻吩-二氰基乙烯基的聚集诱导的发射性质4 - 6（A-d-A”型分子构型）的报告。的光学性质4 - 6可以通过审慎地改变缺电子硼和二氰基乙烯基单元之间的噻吩单元的数目来调节。与具有噻吩间隔基的化合物5和4相比，具有噻吩间隔基的化合物6分别显示出高度红移的吸收和发射。化合物5和6在水/ THF混合物中显示出聚集诱导的排放增强。化合物5和6还显示出取决于溶剂粘度的发射特性。对于小阴离子（例如氟和氰化物），所有这三种化合物均显示出不同的光学响应。涂有化合物的滤纸条5和6可以检测˚F -和CN -在具有不同的比色反应的水性介质。
• Therapeutic compounds
  申请人：——

  公开号：US20040229910A1

  公开（公告）日：2004-11-18

  The present invention relates to certain novel benzylamine derivatives, to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, particularly in the treatment of depression.

  本发明涉及某些新型苄基胺衍生物，其制备过程，含有它们的制药配方以及它们在医学治疗中的应用，特别是在抑郁症治疗中的应用。
• NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF
  申请人：Eisai Co., Ltd.

  公开号：EP1382603A1

  公开（公告）日：2004-01-21

  The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. Inparticular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, X represents a nitrogen-containing condensed aromatic heterocyclic group such as imidazo[1,2-a]pyridine, benzimidazole, quinazoline, quinoline, or 2,1-benzisoxazole and has (R4)n as substituent groups; Y represents a C3-8 cycloalkyl group, C4-8 cycloalkenyl group, 5- to 14-membered non-aromatic heterocyclic group, C6-14 aromatic hydrocarbon cyclic group or 5- to 14-membered aromatic heterocyclic group; n in (R4)n is 0, 1, 2 or 3, and Z groups independently represent (1) hydrogen atom, (2) amino group, (3) halogen atom, (4) hydroxyl group, (5) nitro group, (6) cyano group, (7) azido group, (8) formyl group, (9) hydroxyamino group, (10) sulfamoyl group, (11) guanodino group, (12) oxo group, (13) C2-6 alkenyl group, (14) C1-6 alkoxy group, (15) C1-6 alkylhydroxyamino group, (16) halogenated C1-6 alkyl group, (17) halogenated C2-6 alkenyl group, (18) (i) C3-7cycloalkyl group, (ii) C3-7cycloalkenyl group, (iii) 5- to 14-membered non-aromatic heterocyclic group, each of which may have one or more substituent groups Q, or (19) formula -M1-M2-M3, R1 represents (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) nitro group, (5) cyano group, (6) halogenated C1-6 alkyl group, (7) C2-6 alkyl group substituted with a hydroxyl or cyano group, (8) C2-6 alkenyl group, or (9) formula -L1-L2-L3, and R2 represents a hydrogen atom or a protecting group; and R3 represents a hydrogen atom, halogen atom, cyano group, amino group, C1-4 alkyl group or halogenated C1-4 alkyl group.

  本发明提供了一种对 STAT6 的活化具有极佳抑制作用的化合物及其药物组合物。特别是提供了由下式（I）代表的化合物、其盐或它们的水合物。 式中，X代表含氮缩合芳香杂环基团，如咪唑并[1,2-a]吡啶、苯并咪唑、喹唑啉、喹啉或2,1-苯并异噁唑，并有(R4)n作为取代基；Y代表C3-8环烷基、C4-8环烯基、5～14元非芳香杂环基团、C6-14芳香烃环基或5～14元芳香杂环基团；(R4)n 中的 n 是 0、1、2 或 3，Z 基团独立地代表：(1) 氢原子，(2) 氨基，(3) 卤素原子，(4) 羟基，(5) 硝基，(6) 氰基，(7) 叠氮基，(8) 甲酰基，(9) 羟基氨基、(10) 氨基磺酰基，(11) 氨基胍基，(12) 氧代基，(13) C2-6 烯基，(14) C1-6 烷氧基，(15) C1-6 烷基羟基氨基，(16) 卤代 C1-6 烷基，(17) 卤代 C2-6 烯基，(18) (i) C3-7 环烷基、(ii) C3-7 环烯基，(iii) 5-14 元非芳杂环基团，其中每个基团可有一个或多个取代基 Q，或 (19) 式-M1-M2-M3，R1 代表 (1) 氢原子，(2) 卤素原子，(3) 羟基、(4) 硝基，(5) 氰基，(6) 卤代 C1-6 烷基，(7) 被羟基或氰基取代的 C2-6 烷基，(8) C2-6 烯基，或 (9) 式-L1-L2-L3，R2 代表氢原子或保护基团；R3 代表氢原子、卤素原子、氰基、氨基、C1-4 烷基或卤代 C1-4 烷基。
• Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2048142A2

  公开（公告）日：2009-04-15

  The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. In particular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, the groups X,Y,Z,R1-R4 and n are defined as in claim 1.

  本发明提供了一种对 STAT6 的活化具有极佳抑制作用的化合物及其药物组合物。特别是提供了由下式（I）代表的化合物、其盐或它们的水合物。 式中，基团 X、Y、Z、R1-R4 和 n 的定义如权利要求 1 所述。